Full Press Release Details
Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance.
BIIB
Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance
Key Takeaway: Biogen Idec Total Revenues Increased 32% to $1.8 Billion in Third Quarter; Company Raises 2013 Financial Guidance
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis